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There has certainly been a progression in the approach to locally 
advanced non-small cell lung cancer over the last two decades. Until 
the 1980s, radiation therapy alone had been the standard of care for 
locally advanced NSCLC despite the dismal survival data. During the 
early 1990s, results of multiple randomized phase III studies shifted the 
standard toward concurrent chemoradiation therapy. 
The mechanism of chemotherapeutic radiosensitization is thought to be 
direct inhibition of radiation-induced damage repair; elimination of ra-
dioresistant, chemosensitive clones; and/or suppression of inter-fraction 
tumor repopulation. Concurrent chemoradiation addresses both distant 
and locoregional disease simultaneously. The two modalities should act 
synergistically on tumor clonogens susceptible to both modality and in 
a complementary fashion on locoregional clonogens that are suscep-
tible to only one of the modalities. A number of phase III randomized 
trials have shown a statistically signiﬁcant improvement in clinical 
outcomes, including survival, with the concurrent approach. However, 
this aggressive strategy has also led to an increase in the incidence and 
severity of treatment-related toxicities.
These innovations in treatment now begin to cooperate with improve-
ments in the imaging of cancers like PET scanning and with the im-
provements in computers and automation that are allowing us to deliver 
radiation in a more conformal fashion than before to reduce toxicity 
while improving tumor control. The implication of these new technolo-
gies in treating lung cancers is really quite profound. New treatment 
planning systems allow for the delivery of more targeted radiation with 
multiple, non-traditional ﬁeld arrangements when needed to protect 
normal structures. Areas of atelectatic lung remain a challenge for the 
radition oncologist to be able to adequately deﬁne the target volume. 
However, incorporation of the physiologic data provided by PET scan-
ning may not only allow physicans to spare the collapsed lung but may 
allow them to deliver higher doses of radiation to more biologically 
active and presumably more aggressive areas of tumors as well. 
Advances in radiation therapy (RT) techniques, chemotherapeutic 
regimens, and different combined-modality approaches have yielded a 
modest impact on the prognosis of patients with advanced lung cancer. 
But the median survival for locally advanced NSCSL patients is only 
18-24 month at best. There is clearly a need for additional strategies. 
Recent discoveries in molecular biology have identiﬁed a number of 
molecular determinants that may be responsible for resistance of cancer 
cells to radiation or other cytotoxic agents, and as such may serve as tar-
gets for augmentation of radio- or chemo-response. Among these deter-
minants are epidermal growth factor receptor (EGFR), Anti Angiogeneis 
agents, mutated ras, angiogenic molecules, and various other molecules 
that regulate different steps in their signal transduction pathways.
Incorporating newer biologic agents into chemoradiotherapy is criti-
cal to further improve outcomes in this setting. One strategy should 
improve therapeutic outcomes by blocking receptors and pathways that 
help tumor cells survive radiation and repair damage without increas-
ing normal tissue toxicity. In this meeting we will review the current 
research challenges in incorporating these agents into radiotherapy 
and chemoradiotherapy and preliminary data in patients with locally 
advanced NSCLC.
E07-02 Treatment of Locally Advanced NSCLC, Mon, Sept 3, 16:00 – 17:30
The role of surgery in the treatment of locally advanced non-small 
cell lung cancer 
Grunenwald, Dominique H. 
Hopital Tenon. University of Paris, Paris, France
Since the TNM system has been applied to lung cancer, patients have 
been paradigmatically subdivided into two subcategories, according 
to surgical possibilities. The surgical landmark was deﬁned precisely 
between stages III A and B, since T3 and/or N2 tumors are world-
widely considered as ﬁt for resection, while T4 and/or N3 are generally 
unresectable [1]. Actually non-small cell lung cancers (NSCLC) should 
be subdivided in three subgroups: 1) patients who could be cured by 
surgery alone, some of them able to beneﬁt from adjuvant strategy; 2) 
patients with so-called marginally resectable locally advanced tumors, 
in which surgical resection alone is generally unable to achieve a 
long-term survival; 3) patients with advanced disease, deﬁnitively not 
amenable to surgery [2]. 
Stage IIIA
Theoretically resectable, stage IIIa disease actually includes a high pro-
portion of non-resectable tumors, particularly because of nodal disease. 
These locally advanced lung cancers have a poor prognosis, related to 
their high potential for distant metastases. According to the hypothesis 
that the tumor debulking induced by neo-adjuvant treatments could 
render resectable some locally advanced NSCLC tumors in selected 
patients, chemotherapy, or chemoradiotherapy, was proposed as induc-
tion pre-operative strategy in stages IIIA patients. A large european 
randomized study comparing induction chemotherapy with primary 
surgery failed to demonstrate the superiority of neoadjuvant treatment 
in stage IIIA category [3]. Contrarily a retrospective study of more 
than 700 resected N2 non-small cell lung cancers showed that those 
preoperatively treated patients achieved a signiﬁcantly better survival 
than patients who did not receive induction chemotherapy [4]. A 
North American Intergroup randomized study, attempted to assess the 
relevance of surgical resection after induction chemo-radiotherapy in 
stage IIIA NSCLC with N2 disease [5]. This trial explored the surgi-
cal question on a very homogeneous group of T1 to T3/N2 disease. 
Preliminary results of INT 0139 showed better survival (38% and 33% 
at 3 years in the surgical and non-surgical arms, respectively) than was 
observed in previous phase II trials (26% for N2 disease at 3 years in 
SWOG 8805[6]). Interstingly, half of the patients (46%) were down-
staged to N0, and for those patients, median survival was 37 months. 
These results emphasize the hypothesis that the absence of tumor in 
the mediastinal nodes at surgery is the strongest predictor of long-term 
survival, as it was previously reported in other studies [4,6,7,8]. A 
prospective approach for future clinical practice could suggest conduct-
ing surgery only on patients who respond at the mediastinal level after 
induction treatment. Another randomized trial in Europe compared 
surgical resection to radiotherapy after induction chemotherapy in stage 
IIIA-N2 non-small cell lung cancer [9]. In this study surgical resection 
did not improve survival in comparison to radiotherapy. Nevertheless, 
an unplanned subgroup analysis performed in the surgery-arm showed 
that mediastinal clearance was a statistically signiﬁcant factor. 
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Stage IIIA also includes lung cancers invading thoracic wall and 
superior pulmonary sulcus tumors. Pancoast’s tumors can be resected 
with overall 5-year survival rates around 30%, in the absence of 
vertebral invasion [10]. Lung cancers invading the thoracic wall (T3) 
are currently resected, by the means of an en bloc procedure in which 
parietal and pulmonary structures are removed together. In the absence 
of mediastinal lymph node involvement, 5-year survival rates of 50% 
were reported [11]. In these last categories of patients, the role of multi-
modality strategy, and particularly the place of radiotherapy, advocated 
by many groups remains to become clearer [12]. 
Stage IIIB
Currently stage IIIb diseases are considered unresectable. Nevertheless, 
selected patients whose T4 tumor is not associated with a mediastinal 
N2 nodal involvement, can be proposed for extended resections, either 
as a primary treatment, of after induction. 
The signiﬁcance of surgical treatment for T4 lung cancer has been stud-
ied by numerous authors, particularly in Japan. For instance, Sakurada 
and his colleagues found 50% and 38% ﬁve-year survival rates after 
resection for lung cancer invading the left atrium and major vessels, 
respectively [13]. The only signiﬁcant prognostic factor they identiﬁed 
was the completeness of resection (p<0.05). In the same way, Shirakusa 
and coll. reviewed their experience in extended operations for T4 lung 
carcinoma [14]. Interestingly the results were found far better in the last 
period of their study (from 1992 to 1997), with a 3-year survival rate of 
25%, compared to the 7% observed in the former period (1978-1989), 
showing an increasing experience in the management of patient’s care. 
Regarding the T4 descriptors from the International Staging System 
separately, some of them, invading mediastinal organs, have been con-
sidered as potentially resectable by several groups. 
Left atrium and great arteries
Proximal tumors from the lower lobe developed around the inferior 
pulmonary vein can extend until the atrial wall of the heart. Fukuse 
and coll. reported a series of 42 patients operated upon for lung cancer 
invading left atrium or great vessels [15]. Overall 3-year survival was 
17%. Great vessels invasions were found to be of better prognosis than 
atrial involvements (p=0.036). 
Superior Vena Cava 
Invasion of the superior vena cava by a T4 tumor coming from the right 
upper lobe led surgical teams to attempting lobectomies or pneumo-
nectomies extended to the vena cava [16]. Actually direct extension to 
the vessel by the tumor mass itself is a rare situation. Usually a vena 
cava resection is needed by extension of a bulky disease, in which the 
nodal disease actually is the most component, and by consequence the 
tumor remains difﬁcult to classify, between N2 or T4. A multicentric 
international review of prosthetic replacement after superior vena cava 
resection for non small cell lung cancer in 28 patients, in which N2 
involvement was present in 50% of the cases, found an overall 5-year 
probability of survival of 15% [17].
Carina, trachea
A bronchial carcinoma from the right lung extended to the lower part 
of the thoracic trachea, and/or the tracheal carina can be resected in 
selected patients [18]. But the largest series in world shows a high rate 
of anastomotic complications (dehiscence or stenosis), who were found 
as predictor of operative mortality (p=0.04). Yatsuyanagi and coll. 
focused their study on anastomotic complications after bronchoplas-
tic procedures [19]. Nodal involvement at postoperative pathological 
examination (pN0-1/N2) was the only clinical predictor of bronchial 
complications. 
Vertebral body 
Tumors involving the transverse process or the lateral part of the 
vertebral body could be resected through an enlarged posterolateral 
thoracotomy [20]. However, direct major invasion of the vertebral body 
remained an absolute contraindication to surgical repair until the ﬁrst 
report in 1996 of a successful total vertebrectomy for en bloc resec-
tion of lung cancer invading the spine [21]. Among the factors who 
determine outcome in patients with superior sulcus tumors treated by 
multimodal approach at the University of Texas MD Anderson Cancer 
Center, surgical treatment was found as a signiﬁcant predictor (p<0.01), 
while vertebral body involvement remained marginally signiﬁcant 
(p=0.05)[22]. At the same institution a multidisciplinary team of 
neurosurgeons and thoracic surgeons attempted to achieve a locore-
gional control, i.e. a negative surgical margin of all areas including the 
involved vertebrae [23]. Preliminary results on 17 patients (median 
follow-up = 25 months) showed no postoperative lethality, consistent 
morbidity, tumor recurrences in half of the cases, and a 2-year survival 
rate of 80% for completely resected patients. In the same way, an 
en-bloc technique of resection was developed in Europe, in attempting 
to respect oncologic principles, by the means of a notouch resectional 
attempt [24]. 
Multimodal approach in stage IIIB
Several reported studies have demonstrated the feasibility of surgical 
resection after induction chemoradiotherapy in patients with stage IIIB 
non-small cell lung cancer [6-8]. Stamatis and his colleagues reported a 
complete resection rate of 48% after bifractionated radiotherapy associ-
ated with chemotherapy given preoperatively in 56 patients with stage 
IIIB disease [25]. Those patients who could be completely resected 
survived at 5 years in 43% of the cases, while overall 5-year survival of 
the entire series was 26%. In our study, surgical resection after induc-
tion chemoradiotherapy achieved an encouraging 28% long-term sur-
vival for patients with stage IIIB disease in whom chemoradiotherapy 
alone failed to control disease [26]. 
In conclusion, the role of surgery in locally advanced non-small cell 
lung cancer remains under investigation. Clearly surgical resection is 
an efﬁcient salvaging procedure for selected stage IIIB patients who 
are partial responders without mediastinal lymph node involvement at 
the time of surgery. Altogether, available data suggest that post-induc-
tion TN status is more accurate than pretreatment TN status to guide 
the indications of surgery for patients with locally advanced NSCLC. 
Several questions remaining: What is the best preoperative strategy to 
increase the rate of mediastinal lymph node downstaging ? How can 
multimodality treatment-induced toxicity be lessened ? Faced with such 
toxicity, should surgery be performed in patients presenting a complete 
response and how can they be identiﬁed preoperatively? 
In addition, the staging system for lung cancer must be adjusted in 
accordance to progress in surgical techniques, allowing extended resec-
tions in the context of multimodality treatments, and particularly taking 
into account the different concepts of documented versus unforeseen 
N2 involvements and potentially resectable versus deﬁnitively nonre-
sectable advanced tumors. 
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Over recent years combined modality therapy has become ﬁrmly es-
tablished as a standard in the treatment of patients with locoregionally 
advanced unresectable non-small cell lung cancer (NSCLC). In direct 
comparison, concomitant chemoradiotherapy was shown repeatedly 
to be superior to induction chemotherapy. A case can be made that 
concomitant chemoradiotherapy primarily addresses locoregional dis-
ease while induction chemotherapy might be better suited to eradicate 
distant micrometastatic foci. Therefore, continuing sequential and con-
comitant therapy might be beneﬁcial and the addition of induction or 
adjuvant chemotherapy to the concomitant chemoradiotherapy standard 
have been investigated. 
CALGB 39801 compared concomitant chemoradiotherapy using the 
carboplatin paclitaxel platform versus induction chemotherapy with 
carboplatin and paclitaxel for two cycles followed by identical chemo-
radiotherapy. While a numerical trend favored the induction chemo-
therapy arm, there was no signiﬁcant advantage for overall survival. 
Similarly, the Hoosier Oncology Group evaluated the administration of 
concomitant chemoradiotherapy using the cisplatin etoposide platform 
with or without three additional cycles of consolidation chemotherapy 
with docetaxel. This study was based on promising pilot data generated 
by the Southwest Oncology Group. Again, the study showed no signiﬁ-
cant survival advantage from the addition of concomitant chemoradio-
therapy. Therefore, at the present time, concomitant chemoradiotherapy 
should be regarded as the standard approach for most patients with 
unresectable non-small cell lung cancer. 
Induction chemotherapy may have a role for patients with poor perfor-
mance status who may not be candidates to undergo aggressive chemo-
radiotherapy. Certain targeted agents might be appropriate to investi-
gate in the consolidation setting under carefully deﬁned experimental 
conditions. This need is highlighted by the recent experience in SWOG 
0023 in which the administration of geﬁtinib as maintenance therapy 
was found to decrease survival rates. 
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The lung is an internal organ consisting of a complex branching system 
of airways leading to gas exchange units. Lung cancer consists of 
several cell types instead of a single cell type. Different cell types are 
preferentially located in different parts of the bronchial tree. There is no 
single method that can detect pre-invasive cancer in the entire bronchial 
epithelium and allow simultaneous tissue sampling for pathological 
diagnosis and molecular proﬁling. While computerized tomography, 
magnetic resonance imaging and ultrasound can detect objects in the 
sub-milliliter scale, photonic imaging can detect structural and func-
tional changes in cells and tissues down to the micron and sub-micron 
